首页> 外文期刊>Biotechnology Progress >Process and operations strategies to enable global access to antibody therapies
【24h】

Process and operations strategies to enable global access to antibody therapies

机译:过程和运营策略,以实现全球对抗体治疗的进入

获取原文
获取原文并翻译 | 示例
       

摘要

Few monoclonal antibodies are currently approved for treating infectious diseases, but multiple products are in development against a broad range of infectious diseases, including Ebola, influenza, hepatitis B, HIV, dengue, and COVID-19. The maturity of mAb technologies now allow us to identify and advance neutralizing mAb products to the clinic at "pandemic pace", as the pipeline of mAbs targeting SARS-CoV-2 has demonstrated. Ensuring global access to these products for passive immunization, however, will require both low manufacturing cost and multi-ton production capacity-particularly for those infectious diseases where the geographic burden falls mostly in low- and middle-income countries or those with pandemic potential. Analysis of process economics and manufacturing technologies for antibody and other parenteral protein therapeutics demonstrates the importance of economies of scale to reducing the cost of goods for drug substance manufacturing. There are major benefits to convergence on a standardized platform process for antibody production that is portable to most existing very large-scale facilities, carries low risk for complications during process transfer and scale-up, and has a predictable timeline and probability of technical and regulatory success. In the case of an infectious disease with pandemic potential which could be treated with an antibody, such as COVID-19 or influenza, these advantages are paramount.
机译:目前批准了几种单克隆抗体用于治疗传染病,但多种产品正在开发出广泛的传染病,包括埃博拉,流感,乙型肝炎,艾滋病毒,登革热和Covid-19。 MAB技术的成熟现已允许我们以“大流行速度”识别和提前中和MAB产品,因为靶向SARS-COV-2的MAB管道。然而,确保全球对被动免疫产品的进入,需要低制造成本和多吨的生产能力 - 特别是对于那些地理负担主要在低收入和中等收入国家或具有大流行潜力的人的传染病。对抗体和其他肠胃外蛋白质治疗方法的过程经济学和制造技术的分析表明了规模经济的重要性降低了降低药物制造商品的成本。在标准化平台过程中收敛有重大好处,用于抗体生产,该过程可用于大多数现有的大规模设施,在流程转移和扩大过程中的并发症风险低,具有可预测的时间表和技术和监管的可能性成功。在具有大流行潜力的传染病的情况下,可以用抗体处理,例如Covid-19或流感,这些优点是至关重要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号